Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | myelin-associated glycoprotein |
Clinical data | |
Other names | GSK249320 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6608H10156N1732O2064S44 |
Molar mass | 148298.64 g·mol−1 |
Refanezumab (GSK249320) is a monoclonal antibody designed for the recovery of motor function after stroke. [1] [2]
This drug was developed by GlaxoSmithKline.